Yes, Continue Current Antimicrobial Regimen Unchanged
With normal blood tests and no signs of toxicity, you should continue the ertapenem-meropenem regimen as prescribed, provided the patient is showing clinical improvement and source control has been achieved. Normal laboratory values indicate the drugs are being tolerated without evidence of hematologic, hepatic, or renal toxicity.
Clinical Decision Framework
When to Continue Current Therapy
The 2010 IDSA/SIS guidelines for complicated intra-abdominal infections explicitly state that lower-risk patients with community-acquired infection do not require alteration of therapy if a satisfactory clinical response occurs, even if unsuspected pathogens are later reported 1. This principle applies when:
- Clinical improvement is evident (defervescence, decreasing inflammatory markers, improved hemodynamics)
- Source control was adequate
- No new signs of infection emerge
- Laboratory monitoring shows no drug toxicity
Monitoring Parameters to Assess
While blood tests are normal now, continue monitoring:
- Renal function: Both ertapenem and meropenem require dose adjustment when creatinine clearance falls below 50 mL/min 2
- Hepatic function: Though meropenem shows no effects from liver disease, periodic assessment is advisable with prolonged therapy 2
- Hematologic parameters: Periodic assessment during extended courses 1
Special Considerations for the Double Carbapenem Regimen
If you're using ertapenem plus meropenem specifically for carbapenem-resistant organisms, this combination has demonstrated:
- Bactericidal activity against pan-drug resistant K. pneumoniae in time-kill studies 3
- 49% one-month survival in salvage therapy for carbapenem-resistant K. pneumoniae bacteremia 4
- Successful outcomes in 3 of 4 critically ill patients with carbapenem-resistant infections 3
The mechanism involves ertapenem's high affinity for carbapenemases, which protects meropenem from degradation 5.
Common Pitfalls to Avoid
Do not discontinue therapy prematurely based solely on normal labs. The decision to continue or modify should be driven by:
- Clinical response (primary determinant)
- Adequacy of source control
- Culture and susceptibility results if available
- Duration appropriate for the infection type
Watch for Clostridioides difficile: Both carbapenems carry risk of CDAD, which can occur up to 2 months after administration 6. If diarrhea develops, consider this diagnosis.
Avoid inadvertent drug interactions: If the patient is on valproic acid, be aware that carbapenems can reduce valproic acid levels and increase seizure risk 6.
Duration Considerations
For complicated intra-abdominal infections, typical duration is 4-7 days after source control, though this should be individualized based on clinical response 1. Normal blood work supports that the patient is tolerating therapy well and can complete the intended course.
The physical compatibility of ertapenem and meropenem has been established in certain IV solutions, though meropenem stability is concentration and temperature-dependent 7.